SPOTLIGHT -
Thomas Marron, MD, PhD, on the Value of Neoantigen Vaccines and Future Research
Marron spoke about the value that neoantigen vaccines can provide by studying T-cell responses and the characteristics of lymphoid response to antigens.
Thomas Marron, MD, PhD, on the Next Steps in Phase 1 Trial Investigating PGV-001
Marron discussed the next steps to a trial of PGV-001, specifically centered around determining the immunogenicity of vaccinated patients against their antigens.
Thomas Marron, MD, PhD, on Research Design for the Neoantigen Peptide Vaccine, PGV-001
Marron detailed the research process for a phase 1 trial of PGV-001 presented virtually at the American Association for Cancer Research Annual Meeting 2021.
Thomas Marron, MD, PhD, on the Safety, Feasibility, and Immunogenicity of Neoantigen Peptide Vaccine PGV-001
Marron discussed the primary objectives and early data from a phase 1 trial presented at the virtual AACR Annual Meeting regarding the neoantigen peptide vaccine, PGV-001.
